Critical appraisal of health-state utility values used in breast cancer-related cost–utility analyses
- 11 May 2017
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 164 (3) , 527-536
Abstract
To review the data sources of health-state utility values (HSUVs), as well as their elicitation and use, in 140 breast cancer-related cost–utility analyses (CUAs), and to provide a critical appraisal of these.Keywords
This publication has 20 references indexed in Scilit:
- Reporting of Patient-Reported Outcomes in Randomized TrialsJAMA, 2013
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Utility values in National Institute for Health and Clinical Excellence (NICE) Technology AppraisalsValue in Health, 2011
- Health-state utility values in breast cancerExpert Review of Pharmacoeconomics & Outcomes Research, 2010
- The Use of QALY Weights for QALY CalculationsPharmacoEconomics, 2008
- Reporting research results: A moral obligation for all researchersCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2007
- Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancerExpert Opinion on Pharmacotherapy, 2005
- EuroQol: the current state of playHealth Policy, 1996
- Multi-Attribute Preference FunctionsPharmacoEconomics, 1995
- Social preferences for health states: An empirical evaluation of three measurement techniquesSocio-Economic Planning Sciences, 1976